D2R knockdown inhibits CRC proliferation via the β‐catenin/ZEB1 signaling pathway, while the D2R antagonist domperidone suppresses tumor growth by blocking the MEK/ERK/STAT3 and JAK2/STAT3 signaling pathways [48]. The gene discussed is DRD2; the disease is colorectal carcinoma.